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Abstract
Background: Inheritance of a mutation in either BRCA1 or BRCA2 accounts for approximately 5% of all breast
cancer cases, but varies by country. Investigations into the contribution of BRCA mutations to breast cancer
incidence in Greece have been, for the most part, limited by small sample sizes and by the use of cases selected
for their family history of cancer. The aim of the current study was to estimate BRCA mutation frequencies in breast
cancer patients unselected for family history.
Methods: To do so, we enrolled 127 unselected women with breast cancer from the Alexandra Hospital in Athens,
Greece, a large public hospital in the city. Mutations in BRCA1 and BRCA2 were detected using a combination of
techniques and were confirmed by direct sequencing. Two large genomic deletions were sought using mutation-
specific assays. A detailed family history of cancer was obtained from each patient.
Results: We were able to successfully complete testing on samples from 127 women. Among these, six mutations
were identified (four in BRCA1 and two in BRCA2) representing 4.7% of the total or 9.5% of cases diagnosed before
age forty. None of the mutation carriers had a family history of breast or ovarian cancer. Three of the four BRCA1
mutations were in exon 20: two were a G5331A mutation and the third was a 3.2 kb deletion. The fourth BRCA1
mutation was the 3819delGTAAA in exon 11. The two BRCA2 mutations were in exon 11 (3782del10 and 4512insT).
Conclusions: The G5331A mutation in BRCA1 appears to be a founder mutation in the Greek population.
Background
The inheritance of a deleterious mutation in one of the
two breast cancer susceptibility genes, BRCA1 and
BRCA2, is associated with a high lifetime risk of breast
cancer, currently estimated at 80% by the age of 70
[1-3]. Deleterious mutations in both genes also increase
the lifetime risks of ovarian cancer and predispose men
and women to a range of other malignancies [4-6]. Fac-
tors that aid in predicting whether a mutation has been
inherited by a woman with breast cancer include the
number of breast and/or ovarian cancer patients in the
family, the age of diagnosis, her ancestry and various
pathological features of the breast cancer [7,8].
In North America, Europe, Israel and Australia,
women considered to be at high-risk due to a significant
family history of breast cancer may undergo molecular
testing for mutations in BRCA1 and BRCA2. Genetic
screening provides the opportunity for unaffected
women who are identified as a carrier of a deleterious
mutation to consider various risk-reducing options (e.g.,
prophylactic mastectomy and/or oophorectomy, tamoxi-
fen) [9], intensive screening/surveillance (e.g., annual
MRI, mammography) [10], and for women with cancer,
the opportunity for individualized cancer therapy [8].
Exploring the prevalence of BRCA mutations in Greek
patients will help establish whether the implementation
of genetic services is warranted in that country.
A number of studies have evaluated the BRCA muta-
tion status of breast cancer patients in Greece [11-15].
These studies have found that the common Ashkenazi
Jewish mutation, 5382insC and G5331A [16], are possi-
ble founder mutations in the Greek population.
Although these studies provide evidence for a role of
genetics in the etiology of breast cancer in Greece, they
have been limited by their small study population and
the use of cases selected for a family history of cancer.
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Evaluation of a large Greek population of unselected
cases will provide more accurate and unbiased evidence
for risk associated with BRCA mutations and may lead
to the detection of additional founder mutations. We
performed mutation analysis of BRCA1 and BRCA2 on




We conducted a study of unselected breast cancer
patients, diagnosed at or before age 80, in Athens,
Greece from February 10, 2006 to April 26, 2008.
Patients were recruited from a single large public hospi-
tal in Athens (Alexandra Hospital). The study popula-
tion consisted of patients undergoing treatment for a
recent diagnosis of breast cancer. Unselected, newly
diagnosed breast cancer cases were identified from the
breast cancer clinic at Alexandra Hospital. Cases were
approached about the study during their visit to the
hospital. The study was introduced and described to the
patient by the breast surgeon or research assistants. If
the patient agreed to participate, she was provided a
written description of the study, including a consent
form. The patient was informed of the implications of
genetic testing. At the time of the clinic appointment, a
risk factor questionnaire was completed and a family
history was recorded. A blood sample was obtained for
DNA extraction. Mutation analysis took place in the
laboratory of Dr. Steven Narod (Toronto, Canada). The
institutional review boards at the participating centers
approved the protocol and all of the women in the
study provided written informed consent.
Patients were identified through the pathology and
surgical records of the breast cancer service and were
invited to participate through a special invitation. Of
these, 50 were above the age of 80 and were ineligible.
In total, 127 women were included in this study. On
average, 3.7 years had elapsed between the date of diag-
nosis and the date of interview. All participants were
interviewed in person for their family history of cancer,
with specific reference to a history of breast or ovarian
cancer. Tumor histology, tumor size, lymph node invol-
vement and grade were abstracted from the medical
records. Questionnaires on family histories and lifestyle
factors were completed for all 127 cases.
All samples were screened for six common alterations,
and two large genomic deletions, based on previous lit-
erature [11-17]. The common BRCA1 5382insC muta-
tion was detected using a multiplex PCR reaction as
previously described [17]; however, two separate screen-
ing assays were designed using restriction enzymes for
two other BRCA1 mutations G5331A and C5370CT. All
mutations were confirmed through direct sequencing.
The G5586A mutation, which leads to exon 23 skipping
[13], was detected by direct sequencing on all samples,
and previously designed TaqMan Copy Number Varia-
tion Assays (ABI) were used for the large deletions
del3.2kb, and del4429ins5 both in BRCA1. Assay ID
numbers are available upon request. Protein truncation
testing (PTT) was used to detect BRCA2 mutations
2024del5 and 4147delG in exons 10 and 11, respectively.
PTT was performed using the TNT™ rabbit reticulocyte
lysate system (Promega), involving [35S]methionine/
cysteine (New England Nuclear) for protein detection.
Aberrant and mutation positive bands were sequenced
and confirmed by direct sequencing.
Results
A total of 127 breast cancer patients were tested for
BRCA1 and BRCA2 mutations using a combination of
laboratory techniques. The mean age of the patients at
diagnosis was 50.8 years (range 19.3-78.2 years) and the
average age at interview was 54.4 years (range 24.1-
78.5). Sixteen percent of the patients were diagnosed
before the age of 40 (n = 21) and 49% were diagnosed
before the age of 50 (n = 62). Seventeen (13%) of the
patients had a family history of breast or ovarian cancer
and 13 (10%) of the patients had first-degree relative
diagnosed with breast or ovarian cancer.
Overall, six mutations were identified (4.7%; 95%CI
0.018-0.10), including four in BRCA1 (3.1%) and two in
BRCA2 (1.6%) (Table 1). Three of the four BRCA1
mutations were in exon 20: two were the G5331A
mutation and the third was the 3.2 kb deletion. The
fourth BRCA1 mutation was 3819delGTAAA in exon11.
Both the BRCA2 mutations were in exon 11 (3782del10
and 4512insT). A mutation was seen in two of 21
patients diagnosed with breast cancer before age 40
(9.5%), in two of 46 patients diagnosed between ages of
40 and 50 (4.3%) and in two of 60 cases diagnosed
above age 50 (3.3%). One of the six mutation carriers
had a family history of breast or ovarian cancer and a
first-degree relative diagnosed with breast or ovarian
cancer (16.7%).
Discussion
The aim of the current study was to estimate the preva-
lence of BRCA mutations in a series of unselected
female breast cancer cases from Greece. We identified a
deleterious BRCA1 or BRCA2 mutation in 4.7% of the
women with breast cancer. The most common mutation
was the G5331A mutation, accounting for 1.6% of the
cancers diagnosed and 33% of all mutations. Four addi-
tional mutations were identified; two in BRCA1 and two
in BRCA2. Other studies of unselected populations have
reported relatively low BRCA mutation frequencies
(range: BRCA1 0-7%; BRCA2 1-3%) (reviewed in [18]).
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One other hospital-based study has evaluated the fre-
quency of BRCA1 (but not BRCA2) mutations among
unselected breast cancer cases in Greece [19]. The
authors evaluated the prevalence of four specific BRCA1
mutations. They previously reported that these account
for 54% of all mutations detected in both genes [19].
They found that 26 of the 987 patients (2.6%) carried
one of four mutations in BRCA1: 5382insC (1.3%),
5331G>A (0.4%), and two large genomic rearrangements
involving deletions of exons 20 (0.3%) and 24 (0.6%).
5382insC has been previously described in numerous
populations while the latter three mutations have only
been described in Greek populations. Further, 14 of the
26 (54%) carriers had an early age of diagnosis (<40
years) and 10% of all the early-onset patients carried
one of the four mutations. Given that the original data
was based on the testing of 287 Greek families with a
history of breast and/or ovarian cancer, this was not a
study of unselected patients.
Nearly all the other prior studies evaluating BRCA
mutation frequencies among patients in Greece have
included women with familial breast and/or ovarian can-
cer (i.e., those with a family history) while the women in
the current study were unselected for a personal or
family history of cancer [11-16]. In the most compre-
hensive of these studies, the authors identified 26 BRCA
mutations (15 BRCA1 and 11 BRCA2) in 287 Greek
breast/ovarian cancer families using dHPLC followed by
direct sequencing [16]. Four BRCA1 mutations
accounted for more than half of the identified muta-
tions, while the remaining 22 mutations were a mixture
of unique mutations occurring at a low frequency sug-
gesting a genetically heterogenous population [20]. The
5382insC and G5331A mutations in exon 20 of BRCA1
accounted for 46% of the families. We did not detect
the 5382insC frameshift mutation in our study popula-
tion. Although the 5382insC mutation is known as a
founder mutation in the Ashkenazi Jewish population,
Hamel et al. recently estimated that this mutation likely
arose approximately 1,800 years ago in Scandinavia or
northern Russia and infiltrated the Ashkenazi Jewish
population 400-500 years ago [21]. Further, the authors
concluded that this is likely the most common mutation
in many European countries.
Relatively few BRCA mutations account for BRCA-
associated cancers among homogenous populations such
as Iceland and Poland, while more heterogeneous popu-
lations such as in Canada or the United States tend to
display a broad mutation spectrum [18,22,23]. Founder
mutations are specific mutations that appear repeatedly
in ethnically defined groups because of a shared com-
mon ancestry. Such mutations have been identified in
Icelandic [24], Polish [25], French-Canadian [26], and
Ashkenazi Jewish [27], among other, populations. If
genetic testing is to be offered to high-risk individuals, it
is more economical to screen for founder mutations
rather than comprehensive genetic testing which is con-
siderably more costly.
Based on our and prior findings [14,16,28], it appears
that G5331A mutation in BRCA1 may be a founder
mutation in the Greek population. Previous studies indi-
cate that the 5382insC frameshift [11,13,14,16,21] is
likely a founder mutation as well, although this was not
the case in the current study. In addition to these two
mutations, many others reported several novel muta-
tions, deletions or genomic rearrangements as well as
unclassified variants and [11,12,15,16,19] suggesting a
genetically heterogeneous population.
A major strength of the current study were the inclu-
sion of unselected breast cancer cases thus allowing for
an accurate estimation of the proportion of cases due to
BRCA mutations. Further, genetic testing for BRCA1
and BRCA2 is highly sensitive [29]. Nonetheless, we
were limited by the relatively small sample size (n =
127). The majority of the aforementioned studies were
limited by the inclusion of familial cases, the relatively
small sample sizes (n range 25-287) and the screening
of one rather than both BRCA genes.
Conclusions
Inheritance of a deleterious BRCA mutation is one of
the most important predictors of an individual’s risk of
developing breast cancer. Given that breast cancer is the
most commonly diagnosed malignancy among women
in Greece, it is of value to identify those at a high-risk
of developing the disease. Genetic screening provides
the opportunity for women identified as carriers of a
deleterious mutation to consider various prevention
Table 1 BRCA1 and BRCA2 Mutations Found in Greek Breast Cancer Patients
Patient Gene Exon Mutation Age at diagnosis Family history of breast or ovarian cancer
31617 BRCA1 20 3.2 kb deletion 59.05 Yes
31638 BRCA1 20 G5331A 46.12 None
31652 BRCA1 11 3819delGTAAA 40.96 None
31669 BRCA1 20 G5331A 23.03 None
33319 BRCA2 11 4512insT 38.50 None
33328 BRCA2 11 3782del10 56.22 None
Koumpis et al. Hereditary Cancer in Clinical Practice 2011, 9:10
http://www.hccpjournal.com/content/9/1/10
Page 3 of 4
strategies (e.g., prophylactic mastectomy and/or oophor-
ectomy, tamoxifen) [9] or intensive screening (e.g.,
annual MRI, mammography) [10] to help lessen the
burden of this disease.
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